The influence of macrophages and the tumor microenvironment on natural killer cells

Current Molecular Medicine

Volumn 13, Issue 1, 2013, Pages 68-79

  Krneta, T ^a   Gillgrass, A ^a   Ashkar, A A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Immunosuppression; Tumor microenvironment; Tumor associated macrophages (TAMs); Tumor associated NK cells

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD27 ANTIGEN; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MANNOSE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL PROLIFERATION; CYTOKINE RELEASE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; METASTASIS; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; PHAGOCYTOSIS; POLARIZATION; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW;

CELL PROLIFERATION; DINOPROSTONE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KILLER CELLS, NATURAL; MACROPHAGES; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84884358740     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652413804486269     Document Type: Article

References (120)

1. Luci C, Tomasello E. Natural killer cells: detectors of stress. Int J Biochem Cell Biol 2008; 40(11): 2335-40.
2. Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organspecific features of natural killer cells. Nat Rev Immunol 2011; 11(10): 658-71.
3. Hoglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 2010; 10(10): 724-34.
4. Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12(9): 1065-74.
5. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011; 2011: 676198.
6. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331(6013): 44-9.
7. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27(45): 5932-43.
8. Liu RB, Engels B, Arina A, et al. Densely Granulated Murine NK Cells Eradicate Large Solid Tumors. Cancer Res 2012; 72(8): 1964-74.
9. Pietra G, Manzini C, Rivara S, et al. Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity. Cancer Res 2012; 72(6): 1407-15.
10. Balsamo M, Scordamaglia F, Pietra G, et al. Melanomaassociated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 2009; 106(49): 20847-52.
11. Zhou H, Chen LJ, You Y, Zou L, Zou P. Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner. Autoimmunity 2010; 43(4): 299-307.
12. Smyth MJ, Teng MWL, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4(+)-CD25(+) T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176(3): 1582-7.
13. Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol 2009; 86(5): 1105-9.
14. Solinas G, Germano G, Mantovani A, Allavena P. Tumorassociated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86(5): 1065-73.
15. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4(1): 71-8.
16. Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 2008; 10(8): 775-83.
17. Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR, Wiltrout RH. NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol 1996; 156(12): 4707-14.
18. Glas R, Franksson L, Une C, et al. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cellmediated responses. J Exp Med 2000; 191(1): 129-38.
19. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer celldeficient mice. Proc Natl Acad Sci USA 2000; 97(6): 2731-6.
20. Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28(4): 571-80.
21. Street SE, Zerafa N, Iezzi M, et al. Host perforin reduces tumor number but does not increase survival in oncogenedriven mammary adenocarcinoma. Cancer Res 2007; 67(11): 5454-60.
22. Fehniger TA, Cai SF, Cao X, et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 2007; 26(6): 798-811.
23. Takeda K, Smyth MJ, Cretney E, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cellmediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 2001; 214(2): 194-200.
24. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003; 19(4): 561-9.
25. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10(8): 554-67.
26. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27(45): 5944-58.
27. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436(7054): 1186-90.
28. Gillgrass A, Ashkar A. Stimulating natural killer cells to protect against cancer: recent developments. Expert Rev Clin Immunol 2011; 7(3): 367-82.
29. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14: 619-48.
30. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000; 61(1): 65-73.
31. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009; 266(2): 154-81.
32. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22(11): 633-40.
33. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006; 20(3): 123-37.
34. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunol Rev 2006; 214: 47-55.
35. Marcenaro E, Della Chiesa M, Bellora F, et al. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 2005; 174(7): 3992-8.
36. Balsamo M, Vermi W, Parodi M, et al. Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. Eur J Immunol 2012; 42(7): 1833-42.
37. Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y. Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 2006; 108(1): 246-52.
38. Loza MJ, Zamai L, Azzoni L, Rosati E, Perussia B. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 2002; 99(4): 1273-81.
39. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009; 113(22): 5488-96.
40. Fu BQ, Wang FY, Sun R, Ling B, Tian ZG, Wei HM. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology 2011; 133(3): 350-9.
41. Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y. Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 2006; 108(1): 246-52.
42. Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71(16): 5412-22.
43. Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008; 112(4): 863-75.
44. Konjevic G, Mirjacic Martinovic K, Vuletic A, et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24(1): 1-11.
45. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99(10): 3661-7.
46. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 2003; 33(1): 119-24.
47. Gati A, Da Rocha S, Guerra N, et al. Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 2004; 109(3): 393-401.
48. Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996; 88(6): 2279-87.
49. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009; 9(4): 259-70.
50. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11(10): 889-96.
51. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8(12): 958-69.
52. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23(11): 549-55.
53. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164(12): 6166-73.
54. Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70(14): 5728-39.
55. Varin A, Gordon S. Alternative activation of macrophages: immune function and cellular biology. Immunobiology 2009; 214(7): 630-41.
56. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176(1): 287-92.
57. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32(5): 593-604.
58. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-83.
59. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010; 21(1): 27-39.
60. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196(3): 254-65.
61. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193(6): 727-40.
62. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16(2): 91-102.
63. Zhou Z, Zhang C, Zhang J, Tian Z. Macrophages Help NK Cells to Attack Tumor Cells by Stimulatory NKG2D Ligand but Protect Themselves from NK Killing by Inhibitory Ligand Qa-1. PLoS One 2012; 7(5): e36928.
64. Young MR, Wheeler E, Newby M. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J Natl Cancer Inst 1986; 76(4): 745-50.
65. Young MR, Newby M, Meunier J. Relationships between morphology, dissemination, migration, and prostaglandin E2 secretion by cloned variants of Lewis lung carcinoma. Cancer Res 1985; 45(8): 3918-23.
66. Young MR, Endicott RA, Duffie GP, Wepsic HT. Suppressor alveolar macrophages in mice bearing metastatic Lewis lung carcinoma tumors. J Leukoc Biol 1987; 42(6): 682-8.
67. Massague J. TGFbeta in Cancer. Cell 2008; 134(2): 215-30.
68. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13(18 Pt 1): 5262-70.
69. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 2005; 6(6): 600-7.
70. Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003; 100(7): 4120-5.
71. Trotta R, Col JD, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibodydependent cellular cytotoxicity in human NK cells. J Immunol 2008; 181(6): 3784-92.
72. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172(12): 7335-40.
73. Park YP, Choi SC, Kiesler P, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the gammac cytokines and TGF-beta1. Blood. 2011 Sep 15;118(11):3019-27.
74. Wilson EB, El-Jawhari JJ, Neilson AL, et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 2011; 6(9): e22842.
75. Bastos KR, Alvarez JM, Marinho CR, Rizzo LV, Lima MR. Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J Leukoc Biol 2002; 71(2): 271-8.
76. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23(3): 144-50.
77. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007; 26(3-4): 525-34.
78. Holt D, Ma X, Kundu N, Fulton A. Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother 2011; 60(11): 1577-86.
79. Walker W, Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12-and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 2004; 111(3): 298-305.
80. Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 2009; 117(2): 235-42.
81. Joshi PC, Zhou X, Cuchens M, Jones Q. Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J Immunol 2001; 166(2): 885-91.
82. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62(3): 632-5.
83. Diaz-Munoz MD, Osma-Garcia IC, Fresno M, Iniguez MA. Involvement of PGE2 and the cAMP signalling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS-activated macrophages. Biochem J 2012; 443(2): 451-61.
84. Brecht K, Weigert A, Hu J, et al. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J 2011; 25(7): 2408-17.
85. Zorro Manrique S, Duque Correa MA, Hoelzinger DB, et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med 2011; 208(7): 1485-99.
86. Holt DM, Ma X, Kundu N, Collin PD, Fulton AM. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 2012; 35(2): 179-88.
87. Zamanakou M, Germenis AE, Karanikas V. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 2007; 111(2): 69-75.
88. Viola A, Bronte V. Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol 2007; 17(4): 309-16.
89. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by kynurenines. Adv Exp Med Biol 2003; 527: 183-90.
90. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9(10): 1269-74.
91. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196(4): 459-68.
92. Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood 2006; 108(13): 4118-25.
93. Song H, Park H, Kim J, et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol Lett 2011; 136(2): 187-93.
94. Song H, Park H, Kim YS, et al. l-Kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol 2011; 11(8): 932-8.
95. Wang D, Saga Y, Mizukami H, et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol 2012; 40(4): 929-34.
96. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005; 11(16): 6030-9.
97. Seymour RL, Ganapathy V, Mellor AL, Munn DH. A highaffinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol 2006; 80(6): 1320-7.
98. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189(9): 1363-72.
99. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8(6): 467-77.
100. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008; 14(12): 550-9.
101. Tringler B, Zhuo S, Pilkington G, et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 2005; 11(5): 1842-8.
102. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PDL1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006; 8(3): 190-8.
103. Ghebeh H, Tulbah A, Mohammed S, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007; 121(4): 751-8.
104. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
105. Benson DM, Jr., Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116(13): 2286-94.
106. Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71(16): 5393-9.
107. Terme M, Ullrich E, Aymeric L, et al. Cancer-Induced Immunosuppression: IL-18-Elicited Immunoablative NK Cells. Cancer Res 2012; 72(11): 2757-67.
108. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14(10): 3044-51.
109. Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood 2010; 116(17): 3311-20.
110. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2(3): 261-8.
111. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203(4): 871-81.
112. Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67(18): 8900-5.
113. Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum Reprod Update 2012; 18(4): 458-71.
114. Gill S, Vasey AE, De Souza A, et al. Rapid development of exhaustion and downregulation of eomesodermin limits the anti-tumor activity of adoptively transferred murine natural killer cells. Blood 2012; 119(24): 5758-68.
115. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105(8): 3051-7.
116. Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010; 59(12): 1781-9.
117. Mamessier E, Sylvain A, Thibult ML, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121(9): 3609-22.
118. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993; 92(6): 2569-76.
119. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005; 65(8): 3437-46.
120. Bellora F, Castriconi R, Dondero A, et al. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA 2010; 107(50): 21659-64.